AAD
  • Registration
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Topics
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Resources
  • Registration
Facebook iconInstagram iconTwitter icon
Aug 06, 2021

COVID-19: A “predictable surprise”

Former CDC director explores COVID-19 variants, vaccines, and vigilance.


Julie Gerberding, MD, MPH
Julie Gerberding, MD, MPH

Former CDC Director Julie Gerberding, MD, MPH, called COVID-19 a “predictable surprise.” when she delivered the keynote address during the Summer Meeting’s high-interest Plenary (P151) on Friday.

“We have been woefully unprepared for something we knew was a real threat,” Dr. Gerberding said. “For the last 20 years, we’ve known that viruses would be a threat, and we continued to act as if it’s a one-off thing. Unfortunately, we learned the hard way.”

As the former director of the U.S. CDC from 2002-2009 under President George W. Bush, Dr. Gerberding led the agency through severe acute respiratory syndrome (SARS) and more than 40 emergency responses to public health crises, including Hurricane Katrina. 

In 2010, Dr. Gerberding joined Merck as president of vaccines and was instrumental in increasing global access to the company’s vaccines. She is currently executive vice president and chief patient officer at Merck & Co., Inc., where she is responsible for global public policy, communications, patient engagement, corporate social responsibility, and other functions. 

During her address, Dr. Gerberding provided an update on the evolution of COVID-19 and where the virus stands today, specifically looking at variants, vaccines, and vigilance. The variants we are now battling emerged long before vaccines were available, she said. She warned that there are new variants waiting in the wings that will force the need for increased monitoring.  

While improving vaccination rates is critical in the war against COVID-19, Dr. Gerberding said it’s not the first time we’ve been divided over a vaccine program. History reminds us that as far back as our Revolutionary War, the introduction of the smallpox vaccine sparked societal divide, Dr. Gerberding said. Much like today, those opposed to the smallpox vaccine cited safety, scientific uncertainty, and religious objections.

“The smallpox vaccine was incredibly controversial during the Revolutionary War,” she said. “The smallpox vaccine worked. The irony is that today’s vaccines are very safe compared to the vaccines of 200 years ago.”

Dr. Gerberding credits both misinformation and disinformation for low vaccine rates and said there’s a difference between the two. She said the dermatologists play an important role in disseminating facts and improving the vaccination rate.

“Misinformation is when people unknowingly promote things that aren’t true. Disinformation is when people intentionally promote falsehoods,” she said. “Dermatologists should use their influence to advocate for the vaccine. People trust doctors, especially their personal doctors.” She added that the challenge is putting the facts in a common-sense framework that can help more people.

Interesting Stories
What makes a biosimilar and an Interchangeable biosimilar different?
Presented by Boehringer Ingelheim
What makes a biosimilar and an Interchangeable biosimilar different?
Janssen-Sponsored Symposium
Presented by Janssen Biotech, Inc.
Janssen-Sponsored Symposium
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Presented by Pfizer Inc.
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Prurigo Nodularis and Atopic Dermatitis:
Presented by Sanofi and Regeneron Pharmaceuticals, Inc.
Prurigo Nodularis and Atopic Dermatitis:
Join Us to Learn More About SOTYKTU<sup>TM</sup> (deucravacitinib):
Presented by Bristol Myers Squibb
Join Us to Learn More About SOTYKTUTM (deucravacitinib):
Advancing Therapeutic Conversations
Presented by AbbVie
Advancing Therapeutic Conversations
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Presented by Neutrogena
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
More in Summer Meeting 2021
Peter Lio, MD, FAAD
Summer Meeting 2021
The secrets of minimizing pain
Aug 11, 2021
Lawrence S. Chan, MD, FAAD
Summer Meeting 2021
Biomedical advancements impact dermatologic diagnosis and treatment
Aug 11, 2021
Todd Schlesinger, MD, FAAD
Summer Meeting 2021
Update on managing advanced skin cancer
Aug 11, 2021
Hensin Tsao, MD, PhD, FAAD
Summer Meeting 2021
HPV vax, psoriasis biologics, and caregiver quality of life highlight FiRST session
Aug 11, 2021
07e
Summer Meeting 2021
Summer Meeting packed a welcome punch
Aug 11, 2021
Mario E. Lacouture, MD, FAAD
Summer Meeting 2021
Oncodermatology takes the stage at Fox Lectureship
Aug 06, 2021
Aimee Payne, MD, PhD, FAAD
Summer Meeting 2021
Frost Lectureship traces mPV treatment’s path from lab to clinical trial
Aug 06, 2021
2020 Gold Medal Presentation | Professor R. Rox Anderson, MD (left), Lancer Endowed Chair in Dermatology, Harvard Medical School and Director, Wellman Center for Photomedicine at Mass. General Hospital. 2021 Gold Medal Presentation | Dirk Michael Elston, MD, FAAD (right), Medical University of South Carolina.
Summer Meeting 2021
Two physicians honored with AAD Gold Medal awards
Aug 05, 2021
Alina G. Bridges, DO, FAAD
Summer Meeting 2021
New science, technology, and dedication improve dermatopathology
Aug 05, 2021
Sm21 F008 1526e
Summer Meeting 2021
How to have mindful, effective conversations with patients
Aug 05, 2021
Sergey Rekhtman, MD, FAAD, PharmD, MPH, and Sheila Shaigany, MD, FAAD
Summer Meeting 2021
Lessons from COVID-19’s cutaneous manifestations
Aug 05, 2021
Charlene Lam, MD, MPH, FAAD
Summer Meeting 2021
“Uninvite” disaster by planning
Aug 05, 2021
AAD
Facebook iconInstagram iconTwitter icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.